XNYS · Healthcare · Medical Devices
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | 1.86 | 2.62 | +40.86% | $651.0M | ✅ Beat | -1.97% | +7.02% | — |
| 2026-04-30 | Q1 2026 | 2.14 | 1.89 | -11.68% | $592.1M | ❌ Miss | +0.00% | -8.14% | +11.55% |
| 2026-02-12 |
| Q4 2025 |
| 2.65 |
| 2.51 |
| -5.28% |
| $693.2M |
| ❌ Miss |
| -13.83% |
| -7.02% |
| -10.13% |
| 2025-10-29 | Q3 2025 | 2.08 | 2.26 | +8.65% | $653.0M | ✅ Beat | — | — | — |
| 2025-07-31 | Q2 2025 | 1.82 | 2.61 | +43.41% | $651.6M | ✅ Beat | +10.35% | +9.63% | +23.12% |
| 2025-02-13 | Q4 2024 | 2.88 | 2.90 | +0.69% | $667.5M | ✅ Beat | -9.53% | -6.77% | -16.11% |
| 2024-10-30 | Q3 2024 | 1.16 | 2.01 | +73.28% | $649.7M | ✅ Beat | +8.35% | +12.81% | +3.01% |
| 2024-08-01 | Q2 2024 | 2.01 | 3.11 | +54.73% | $638.5M | ✅ Beat | -1.56% | -3.78% | -2.03% |
Showing last 8 quarters.